147 related articles for article (PubMed ID: 15797206)
1. Inhibitex, Inc: antibody anti-infectives.
McCarthy AA
Chem Biol; 2005 Mar; 12(3):257-9. PubMed ID: 15797206
[No Abstract] [Full Text] [Related]
2. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
3. Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases.
Nagy E; Giefing C; von Gabain A
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):21-30. PubMed ID: 18251661
[TBL] [Abstract][Full Text] [Related]
4. Modifying protein misfolding.
Jones D
Nat Rev Drug Discov; 2010 Nov; 9(11):825-7. PubMed ID: 21030987
[No Abstract] [Full Text] [Related]
5. Target selection and pharma industry productivity: what can we learn from technology S-curve theory?
Brown D
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):414-8. PubMed ID: 16889225
[TBL] [Abstract][Full Text] [Related]
6. The long march of antisense.
Jones D
Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
[No Abstract] [Full Text] [Related]
7. Intrabodies as therapeutic agents.
Kontermann RE
Methods; 2004 Oct; 34(2):163-70. PubMed ID: 15312669
[TBL] [Abstract][Full Text] [Related]
8. A dose of reality for rational therapies.
Nat Biotechnol; 2005 Mar; 23(3):267. PubMed ID: 15765066
[No Abstract] [Full Text] [Related]
9. [Do we still need new antibiotics and chemotherapeutic agents?].
Bloch H
Schweiz Med Wochenschr; 1968 Apr; 98(16):611-7. PubMed ID: 5688590
[No Abstract] [Full Text] [Related]
10. Biologics target bad bugs.
Extance A
Nat Rev Drug Discov; 2010 Mar; 9(3):177-8. PubMed ID: 20190776
[No Abstract] [Full Text] [Related]
11. Anti-infectives in the 21st century.
Clough J
Drug Discov Today; 2002 Oct; 7(20):1036-8. PubMed ID: 12546891
[No Abstract] [Full Text] [Related]
12. Intraoral delivery of antimicrobials.
Raj PA; Dentino AR
Drug News Perspect; 2005; 18(6):362-74. PubMed ID: 16247514
[TBL] [Abstract][Full Text] [Related]
13. Identification of anti-infective targets through comparative proteomics.
Burchmore R
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):163-5. PubMed ID: 16597196
[No Abstract] [Full Text] [Related]
14. Eyes on new product development: ophthalmic drug delivery.
Novack GD
J Ocul Pharmacol Ther; 2013 Mar; 29(2):90-1. PubMed ID: 23485090
[No Abstract] [Full Text] [Related]
15. An interview with Doriano Fabbro, Ph.D., Novartis Biomedical Research Institute. Interviewed by Vicki Glaser.
Fabbro D
Assay Drug Dev Technol; 2004 Apr; 2(2):109-14. PubMed ID: 15165506
[No Abstract] [Full Text] [Related]
16. Deal watch: GlaxoSmithKline and Amplimmune join forces on targeting PD1.
Nat Rev Drug Discov; 2010 Oct; 9(10):754. PubMed ID: 20885398
[No Abstract] [Full Text] [Related]
17. Acquisitions not a cure for anti-infectives.
Bradley D
Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178116
[No Abstract] [Full Text] [Related]
18. Deal watch: MSD buys in to emerging epigenetic cancer target.
Cully M
Nat Rev Drug Discov; 2016 Mar; 15(3):153. PubMed ID: 26931086
[No Abstract] [Full Text] [Related]
19. Targeted drug therapy remains a challenge.
Traynor K
Am J Health Syst Pharm; 2011 Dec; 68(24):2320-4. PubMed ID: 22135055
[No Abstract] [Full Text] [Related]
20. Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry.
Eaton MA
J Control Release; 2012 Dec; 164(3):370-1. PubMed ID: 22721816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
